APO RESEARCH · REPORT
Anthrax Vaccines
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
Product & engineering
Understand the product.
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
Selected research
Industry Research
Anthrax Vaccines Industry Research Report 2026
Market perspective
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.
North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.
Read the full market overview
In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.
Report Scope
This report quantifies the global Anthrax Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anthrax Vaccines Market by Company
Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
Biogénesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Santé Animale
Intervac
JOVAC
Anthrax Vaccines Segment by Type
Live Vaccines
Cell free PA Vaccines
Anthrax Vaccines Segment by Application
Human Use
Animal Use
Anthrax Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthrax Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anthrax Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthrax Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anthrax Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anthrax Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Live Vaccines
- Cell free PA Vaccines
Applications
- Human Use
- Animal Use
Companies covered
- Emergent BioSolutions
- Merial
- Merck
- Zoetis
- Bayer Sanidad Animal
- Colorado Serum
- PharmAthene
- Tiankang
- Biogénesis-Bago
- CAVAC
- Rosenbusch
- Agrovet
- Vecol
- CVCRI
- IVPM
- Prondil
- CDV
- Indian Immunologicals
- Botswana Vaccine Institute
- Ceva Santé Animale
- Intervac
- JOVAC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anthrax Vaccines Market Size (2021-2032)
- 2.2.2 Global Anthrax Vaccines Sales (2021-2032)
- 2.2.3 Global Anthrax Vaccines Market Average Price (2021-2032)
- 2.3 Anthrax Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Live Vaccines
- 2.3.3 Cell free PA Vaccines
- 2.4 Anthrax Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Human Use
- 2.4.3 Animal Use
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anthrax Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anthrax Vaccines Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Anthrax Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Anthrax Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Anthrax Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anthrax Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anthrax Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Anthrax Vaccines, Established Date
- 3.9 Global Anthrax Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Emergent BioSolutions
- 4.1.1 Emergent BioSolutions Company Information
- 4.1.2 Emergent BioSolutions Business Overview
- 4.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
- 4.1.5 Emergent BioSolutions Recent Developments
- 4.2 Merial
- 4.2.1 Merial Company Information
- 4.2.2 Merial Business Overview
- 4.2.3 Merial Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merial Anthrax Vaccines Product Portfolio
- 4.2.5 Merial Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Anthrax Vaccines Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Zoetis
- 4.4.1 Zoetis Company Information
- 4.4.2 Zoetis Business Overview
- 4.4.3 Zoetis Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zoetis Anthrax Vaccines Product Portfolio
- 4.4.5 Zoetis Recent Developments
- 4.5 Bayer Sanidad Animal
- 4.5.1 Bayer Sanidad Animal Company Information
- 4.5.2 Bayer Sanidad Animal Business Overview
- 4.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
- 4.5.5 Bayer Sanidad Animal Recent Developments
- 4.6 Colorado Serum
- 4.6.1 Colorado Serum Company Information
- 4.6.2 Colorado Serum Business Overview
- 4.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
- 4.6.5 Colorado Serum Recent Developments
- 4.7 PharmAthene
- 4.7.1 PharmAthene Company Information
- 4.7.2 PharmAthene Business Overview
- 4.7.3 PharmAthene Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PharmAthene Anthrax Vaccines Product Portfolio
- 4.7.5 PharmAthene Recent Developments
- 4.8 Tiankang
- 4.8.1 Tiankang Company Information
- 4.8.2 Tiankang Business Overview
- 4.8.3 Tiankang Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Tiankang Anthrax Vaccines Product Portfolio
- 4.8.5 Tiankang Recent Developments
- 4.9 Biogénesis-Bago
- 4.9.1 Biogénesis-Bago Company Information
- 4.9.2 Biogénesis-Bago Business Overview
- 4.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
- 4.9.5 Biogénesis-Bago Recent Developments
- 4.10 CAVAC
- 4.10.1 CAVAC Company Information
- 4.10.2 CAVAC Business Overview
- 4.10.3 CAVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CAVAC Anthrax Vaccines Product Portfolio
- 4.10.5 CAVAC Recent Developments
- 4.11 Rosenbusch
- 4.11.1 Rosenbusch Company Information
- 4.11.2 Rosenbusch Business Overview
- 4.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
- 4.11.5 Rosenbusch Recent Developments
- 4.12 Agrovet
- 4.12.1 Agrovet Company Information
- 4.12.2 Agrovet Business Overview
- 4.12.3 Agrovet Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Agrovet Anthrax Vaccines Product Portfolio
- 4.12.5 Agrovet Recent Developments
- 4.13 Vecol
- 4.13.1 Vecol Company Information
- 4.13.2 Vecol Business Overview
- 4.13.3 Vecol Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Vecol Anthrax Vaccines Product Portfolio
- 4.13.5 Vecol Recent Developments
- 4.14 CVCRI
- 4.14.1 CVCRI Company Information
- 4.14.2 CVCRI Business Overview
- 4.14.3 CVCRI Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 CVCRI Anthrax Vaccines Product Portfolio
- 4.14.5 CVCRI Recent Developments
- 4.15 IVPM
- 4.15.1 IVPM Company Information
- 4.15.2 IVPM Business Overview
- 4.15.3 IVPM Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 IVPM Anthrax Vaccines Product Portfolio
- 4.15.5 IVPM Recent Developments
- 4.16 Prondil
- 4.16.1 Prondil Company Information
- 4.16.2 Prondil Business Overview
- 4.16.3 Prondil Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Prondil Anthrax Vaccines Product Portfolio
- 4.16.5 Prondil Recent Developments
- 4.17 CDV
- 4.17.1 CDV Company Information
- 4.17.2 CDV Business Overview
- 4.17.3 CDV Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 CDV Anthrax Vaccines Product Portfolio
- 4.17.5 CDV Recent Developments
- 4.18 Indian Immunologicals
- 4.18.1 Indian Immunologicals Company Information
- 4.18.2 Indian Immunologicals Business Overview
- 4.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
- 4.18.5 Indian Immunologicals Recent Developments
- 4.19 Botswana Vaccine Institute
- 4.19.1 Botswana Vaccine Institute Company Information
- 4.19.2 Botswana Vaccine Institute Business Overview
- 4.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
- 4.19.5 Botswana Vaccine Institute Recent Developments
- 4.20 Ceva Santé Animale
- 4.20.1 Ceva Santé Animale Company Information
- 4.20.2 Ceva Santé Animale Business Overview
- 4.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
- 4.20.5 Ceva Santé Animale Recent Developments
- 4.21 Intervac
- 4.21.1 Intervac Company Information
- 4.21.2 Intervac Business Overview
- 4.21.3 Intervac Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Intervac Anthrax Vaccines Product Portfolio
- 4.21.5 Intervac Recent Developments
- 4.22 JOVAC
- 4.22.1 JOVAC Company Information
- 4.22.2 JOVAC Business Overview
- 4.22.3 JOVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 JOVAC Anthrax Vaccines Product Portfolio
- 4.22.5 JOVAC Recent Developments
5 Global Anthrax Vaccines Market Scenario by Region
- 5.1 Global Anthrax Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anthrax Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Anthrax Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Anthrax Vaccines Sales by Region: 2027-2032
- 5.3 Global Anthrax Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Anthrax Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Anthrax Vaccines Revenue by Region: 2027-2032
- 5.4 North America Anthrax Vaccines Market Facts & Figures by Country
- 5.4.1 North America Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anthrax Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Anthrax Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anthrax Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anthrax Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Anthrax Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anthrax Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anthrax Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anthrax Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anthrax Vaccines Market Facts & Figures by Country
- 5.7.1 South America Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anthrax Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Anthrax Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anthrax Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anthrax Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anthrax Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anthrax Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Anthrax Vaccines Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Anthrax Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Anthrax Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Anthrax Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anthrax Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Anthrax Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anthrax Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Anthrax Vaccines Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Anthrax Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Anthrax Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Anthrax Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anthrax Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Anthrax Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anthrax Vaccines Value Chain Analysis
- 8.1.1 Anthrax Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anthrax Vaccines Production Mode & Process
- 8.2 Anthrax Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anthrax Vaccines Distributors
- 8.2.3 Anthrax Vaccines Customers
9 Global Anthrax Vaccines Analyzing Market Dynamics
- 9.1 Anthrax Vaccines Industry Trends
- 9.2 Anthrax Vaccines Industry Drivers
- 9.3 Anthrax Vaccines Industry Opportunities and Challenges
- 9.4 Anthrax Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst